Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188388 | 0.84 | MEN1 (0.41) | MEN1KMT2ARPS6KA5KDM4ELMNA | |
| SCHEMBL188485 | 0.82 | MEN1 (0.40) | MEN1KMT2ARPS6KA5KDM4ELMNA | |
| SCHEMBL188840 | 0.82 | MEN1 (0.40) | MEN1KMT2ARPS6KA5KDM4ELMNA | |
| SCHEMBL188721 | 0.82 | MEN1 (0.44) | MEN1KMT2ARPS6KA5KDM4ELMNA | |
| SCHEMBL188207 | 0.82 | MEN1 (0.39) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL188238 | 0.81 | MEN1 (0.39) | MEN1KMT2ARPS6KA5KDM4E | |
| SCHEMBL188582 | 0.81 | MEN1 (0.39) | MEN1KMT2ARPS6KA5KDM4E | |
| SCHEMBL217160 | 0.81 | MEN1 (0.40) | MEN1KMT2ARPS6KA5KDM4ELMNA | |
| SCHEMBL216481 | 0.80 | KMT2A (0.38) | MEN1KMT2ARPS6KA5KDM4EMAPT | |
| SCHEMBL188453 | 0.80 | NPSR1 (0.39) | MEN1KMT2ARPS6KA5KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | MEN1 3601/4885KMT2A 3701/4885RPS6KA5 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.